Mortality risk with the use of atypical antipsychotics in later-life bipolar disorder

Journal of Geriatric Psychiatry and Neurology

Volumn 25, Issue 1, 2012, Pages 29-36

  Bhalerao, Sachin ^a   Seyfried, Lisa S ^a   Kim, Hyungjin Myra ^b,c,d   Chiang, Claire ^a,c   Kavanagh, Janet ^a   Kales, Helen C ^a,b,c,e  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c VA Serious Mental Illness Treatment Resource and Evaluation Center ^*  (United States)

^d UNIVERSITY OF MICHIGAN   (United States)

^e VA Geriatric Research Education and Clinical Center   (United States)

Author keywords

antipsychotics; bipolar disorder; geriatric

Indexed keywords

OLANZAPINE; QUETIAPINE; RISPERIDONE; VALPROATE SEMISODIUM; VALPROIC ACID;

AGED; ARTICLE; BIPOLAR DISORDER; COHORT ANALYSIS; CONTROLLED STUDY; DEMENTIA; FEMALE; GERIATRIC PATIENT; GOVERNMENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; RISK FACTOR;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BIPOLAR DISORDER; DIBENZOTHIAZEPINES; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; RISPERIDONE; VALPROIC ACID;

EID: 84859373017     PISSN: 08919887     EISSN: 15525708     Source Type: Journal    
DOI: 10.1177/0891988712436687     Document Type: Article

References (24)

1. Meeks S. Bipolar disorder in the latter half of life: symptom presentation, global functioning and age of onset. J Affect Disord. 1999;52(1-3):161-167. (Pubitemid 29232045)
2. Bartels SJ, Forester B, Miles KM, Joyce T. Mental health service use by elderly patients with bipolar disorder and unipolar major depression. Am J Geriatr Psychiatry. 2000;8(2):160.
3. Young RC, Klerman GL. Mania in late life: focus on age at onset. Am J Psychiatry. 1992;149(7):867.
4. Young R. Geriatric mania. Clin Geriatr Med. 1992;8(2):387.
5. Sajatovic M, Blow FC, Ignacio RV, Kales HC. Age-related modifiers of clinical presentation and health service use among veterans with bipolar disorder. Psychiatr Serv. 2004;55(9):1014-1021. (Pubitemid 39209684)
6. Aziz R, Lorberg B, Tampi RR. Treatments for late-life bipolar disorder. Am J Geriatr Pharmacother. 2006;4(4):347-364. (Pubitemid 46211185)
7. Sajatovic M, Calabrese JR, Mullen J. Quetiapine for the treatment of bipolar mania in older adults. Bipolar Disord. 2008;10(6):662-671.
8. Sajatovic M, Gyulai L, Calabrese JR, et al. Maintenance treatment outcomes in older patients with bipolar I disorder. Am J Geriatr Psychiatry. 2005;13(4):305.
9. US Food and Drug Administration. Deaths With Antipsychotics in Elderly Patients With Behavioral Disturbances, in Public Health Advisory. US Department of Health and Human Services; 2005.
10. Transcript for FDA Media Briefing on Safety Labeling Changes for Antipsychotic Drugs; 2008.
11. Kales HC, Kim HM, Zivin K, et al. Risk of mortality among individual antipsychotics in patients with dementia. Am J Psychiatry. 2012;169(1):71-79.
12. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-383. (Pubitemid 17055592)
13. Adamis D, Treloar A, Martin FC, Macdonald AJ. Recovery and outcome of delirium in elderly medical inpatients. Arch Gerontol Geriatr. 2006;43(2):289-298. (Pubitemid 44251228)
14. Kales HC, Kamholz BA, Visnic SG, Blow FC. Recorded delirium in a national sample of elderly inpatients: potential implications for recognition. J Geriatr Psychiatry Neurol. 2003;16(1):32-38. (Pubitemid 37408288)
15. Kales HC, Zivin K, Kim HM, et al. Trends in Antipsychotic Use in Dementia 1999-2007. Arch Gen Psychiatry. 2011;68:190-197.
16. Schneeweiss S, Setoguchi S, Brookhart A, Dormuth C, Wang PS. Risk of death associated with the use of conventional versus atypical antipsychotic drugs among elderly patients. CMAJ. 2007;176(5):627-632. (Pubitemid 46426056)
17. Wang PS, Schneeweiss S, Avorn J, et al. Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N Engl J Med. 2005;353(22):2335-2341. (Pubitemid 41713745)
18. Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA. 2005;294(15):1934-1943. (Pubitemid 41464695)
19. Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika. 1983;70(1):41-55.
20. Kales HC, Valenstein M, Kim HM, et al. Mortality risk in patients with dementia treated with antipsychotics versus other psychiatric medications. Am J Psychiatry. 2007;164(10):1568-1576. (Pubitemid 350069737)
21. Kim HM, Chiang C, Kales HC. After the black box warning: predictors of psychotropic treatment choices for patients with dementia. Psychiatr Serv. 2011;62(10):1207-1214.
22. Vigen CLP, Mack WJ, Keefe RSE, et al. Cognitive effects of atypical antipsychotic medications in patients with Alzheimer's disease: outcomes from CATIE-AD. Am J Psychiatry. 2011;168:831-839.
23. Lyketsos C, et al. Principles of care for patients with dementia resulting from Alzheimer disease, In: Directors B.o., ed. American Association for Geriatric Psychiatry Position Statement. American Association for Geriatric Psychiatry; 2005. http://www.aagponline.org/index.php?src=news&srctype= detail&category=Position%20Statement&refno=35
24. Ballard C, Hanney M, Theodoulou M, et al. The dementia antipsychotic withdrawal trial (DART-AD): long-term follow- up of a randomised placebo-controlled trial. Lancet Neurol. 2009;8(2):151-157.